Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial - Scherpereel, A; Mazieres, J; Greillier, L (Lancet Oncol, 2019)
et al.